apraglutide   Click here for help

GtoPdb Ligand ID: 10685

Synonyms: CVQ1IAY2G6 | FE 203799 | FE203799
Compound class: Peptide
Comment: Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, with amino acid substitutions (Ala2>Gly, Met10>Ahx, Asn11>D-Phe, Asn16>Leu). The peptide's circulating half-life is elevated by the incorporation of Ahx (aminocaproic acid) in place of lysine which reduces degradation by lysine-targeting proteolytic enzymes. Apraglutide enhances adaptation and linear intestinal growth in a neonatal piglet model with total resection of the ileum that mimics human short bowel syndrome [2].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Apraglutide (FE 203799) is being investigated as a therapeutic option for short bowel syndrome [1] and graft-versus-host disease (GvHD). A study of FE 203799 for potential gastro-protective efficacy in chemotherapy-induced intestinal dysfunction/failure was withdrawn (as a business decision).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03408132 Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency Phase 1/Phase 2 Interventional GLyPharma Therapeutic
NCT05018286 Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Phase 3 Interventional VectivBio AG
NCT05415410 Proof-of-concept Trial of Apraglutide in GVHD Phase 2 Interventional VectivBio AG
NCT04627025 Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF Phase 3 Interventional VectivBio AG